F D C

F D C FCF Yield

The Free Cash Flow Yield of F D C (FDC.NS) as of Oct 25, 2026 is 4.02 %. In the previous year, Free Cash Flow Yield was 2.32 % — a change of 73.39% (higher).

FCF Yield

4.02 %

YoY

73.39%

Last updated:

Free Cash Flow Yield of F D C is 2025 4.02 % . Free Cash Flow Yield of F D C was 2024 2.32 % . It decreases by 73.39% higher compared to the previous year.

The F D C FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
2.06 INR
Jan 1, 2019
1.27 INR
Jan 1, 2020
3.99 INR
Jan 1, 2021
2.63 INR
Jan 1, 2022
0.53 INR
Jan 1, 2023
0.76 INR
Jan 1, 2024
2.32 INR
Jan 1, 2025
4.02 INR
The F D C FCF Yield history
YEARFCF YieldYoY
4.02 %+73.39%
2.32 %+204.57%
0.76 %+43.67%
0.53 %-79.86%
2.63 %-34.04%
3.99 %+214.42%
1.27 %-38.22%
2.06 %-12.11%
2.34 %-195.74%
-2.44 %-277.21%
1.38 %-5,349.41%
-0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

Free Cash Flow Yield of F D C is 4.02 % in 2025.

Free Cash Flow Yield of F D C changed from 2.32 % to 4.02 %, representing a 73.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield F D C since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's F D C with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — F D C

All Key Metrics — F D C